Imagine a machine that acts like a temporary external lung, cleaning the blood and adding oxygen without needing a tube down the throat. It lets patients stay awake and breathe on their own while the machine does the heavy lifting of gas exchange. This prevents the dangerous complications that come with traditional ventilators and sedation.
Patients with acute lung failure often face a dangerous jump from non-invasive masks to invasive intubation. This gap leads to high mortality rates and expensive complications in intensive care units.
An integrated system consisting of a compact console and a high-efficiency artificial lung for hyperbaric blood oxygenation.
If you are a medical device manufacturer dealing with the high risks of ventilator-associated lung injury — this project developed a hyperbaric blood oxygenation system that allows patients to remain awake. This provides a safe alternative to invasive mechanical ventilation for up to 6 million patients annually.
If you are a hospital operator dealing with a 35% in-hospital mortality rate for patients on invasive ventilation — this project developed the MiRA system that stabilizes gas exchange without intubation. This reduces the clinical burden and improves patient recovery outcomes.
If you are a therapy provider dealing with the lack of options between non-invasive masks and full intubation — this project developed a miniaturised respiratory assist tool. It fills a critical treatment gap for patients failing non-invasive ventilation.
The market potential is estimated at €10.4 B/year, targeting up to 6 million ALF patients who could benefit from the therapy annually.
The HBOX technology and the specific approach are protected by 2 patents.
The project claims outstanding cost-effectiveness by avoiding or limiting the need for invasive mechanical ventilation, which currently costs thousands of euros per patient.
The project needs to complete clinical studies and obtain MDR/CE certification for the MiRA medical device to commence commercialisation.
The project period runs from 2024-05-01 to 2026-08-31.
The project is led by a single German SME, HBOX Therapies GmbH, representing a 100% industry ratio. This lean structure suggests a fast-track commercialization focus, leveraging a total EU contribution of EUR 2,499,999 to move from animal validation to clinical certification.
Contact HBOX Therapies GmbH in Germany
Contact us to explore licensing opportunities for HBOX hyperbaric technology.
